High-Dose Erythropoietin in Extremely Premature Infants to

Status Terminated

Clinical Trial Summary

The highest risk for perinatal brain injury occurs among extremely premature infants who weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible, associated with neurodevelopmental disability, and without adequate treatment modalities. Research in recent years suggest in both animal and human studies that erythropoietin (Epo) may have significant neuroprotective effects. Given the historical safe medical profile of Epo when used for anemia of prematurity but the likely need for a greater dosage regimen for activation of neuroprotective pathways against neonatal brain injury, we therefore propose this phase II study of high-dose Epo in very low birth weight infants for the prevention and/or attenuation of prematurity-related cerebral hemorrhagic-ischemic injury.

Clinical Trial Description

Eligible extremely premature infants will be enrolled in this double-blind, placebo-controlled randomized trial from the neonatal intensive care unit at Morristown Memorial Hospital (Morristown, New Jersey). Subjects will be enrolled within the first 24 hours of life and randomly assigned to receive Epo or saline vehicle placebo.

Standard NICU care will be provided to all subjects. Serial exams, CBC-d, reticulocyte counts, serum Epo levels, serial HUS, and head MRI will be collected at established time points during the study period. At 18 to 22 months corrected age, subjects will undergo a neurodevelopmental evaluation assessing for cerebral palsy, Bayley Scores of Infant Development-II (BSID-II) Mental Development Index (MDI), BSID-II Psychomotor Development Index (PDI), bilateral hearing aid use, and visual impairment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00589953
Study type	Interventional
Source	Atlantic Health System
Contact
Status	Terminated
Phase	Phase 2
Start date	July 2007
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02710123` - Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion	N/A
Recruiting	`NCT02777060` - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	N/A
Completed	`NCT02262286` - MIND (Management of Traumatic Brain Injury Diagnosis)	N/A
Completed	`NCT01461902` - Vasospasm in Pediatric Traumatic Brain Injury	N/A
Recruiting	`NCT01198964` - Optimization of Human Cortical Stimulation
Active, not recruiting	`NCT01207050` - Effect of Rozerem on Sleep Among People With Traumatic Brain Injury	Phase 4
Completed	`NCT00875329` - Traumatic Brain Injury (TBI) Screening Instruments	N/A
Completed	`NCT01201863` - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy	Phase 4
Completed	`NCT01059890` - Cerebral Antibiotics Distribution After Acute Brain Injury	Phase 1
Completed	`NCT01035606` - Training in Goal-directed Attention Regulation for Individuals With Brain Injury	N/A
Completed	`NCT00571623` - Automated Chest Physiotherapy to Improve Outcomes in Neuro	N/A
Completed	`NCT00596765` - Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury	N/A
Completed	`NCT00336466` - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)	Phase 2
Recruiting	`NCT05105763` - Biofeedback Gait Retraining for Stiff Knee Gait Correction	N/A
Recruiting	`NCT02495558` - Cough Assessment in Patients With Severe Acquired Brain Injury	N/A
Completed	`NCT02100592` - Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study	Phase 1/Phase 2
Completed	`NCT00797680` - Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest	Phase 2
Completed	`NCT00018499` - Genotype Influence on Recovery After Traumatic Brain Injury	N/A
Recruiting	`NCT02567201` - Electrophysiological Evaluation of Voluntary Attention	N/A
Withdrawn	`NCT05581927` - Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms